Company patents
Janssen Pharmaceutica NV
Janssen Pharmaceutica NV's patent strategy shows a surprising shift away from its core "Heterocyclic Compounds" and "Therapeutic Activity (Pharma)" categories, which saw declines of 43.5% and 43.1% respectively in 2025, despite still representing 50.3% and 36.6% of its portfolio. Concurrently, the company is rapidly emerging in "Material & Chemical Analysis" with a 300.0% growth in 2025 and "Peptides & Proteins" with a 114.3% growth in 2025, indicating a strategic pivot towards these areas, although patent counts so far in 2026 show a general slowdown across most categories.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
352 US filings (since 2023) · 11 categories · 24 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.
Devices or systems designed to precisely measure and deliver specific doses of medication, often incorporating automated mechanisms, dose-limiting features, or hands-free operation.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Systems that integrate digital technology, sensors, or connectivity to monitor, track, or automate aspects of medication administration, often providing data feedback, personalized recommendations, or secure logging.
Digital platforms and systems that deliver tailored therapeutic interventions, guidance, or recommendations to patients based on their individual health data, biometric feedback, and computational models (e.g., AI/ML, physiological simulations).
Mechanical or electromechanical systems designed for precise, often self-administered, delivery of medicaments, including features for dose setting, needle insertion/retraction, and safety mechanisms to prevent premature activation.
Systems that monitor a user's actions, performance, or physiological state during a task or activity, and provide immediate or near real-time feedback to guide skill development, correct errors, or verify task completion.
Devices that assist in the physical modification or mixing of medications prior to administration, such as crushing solid drugs, cutting pills, reconstituting lyophilized products, or extracting from other devices.
Integrating game-like mechanics, interactive challenges, and engaging user interface elements (e.g., avatars, reward systems, narrative structures) into educational or therapeutic applications to enhance user motivation, engagement, and learning retention.
Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
The design, fabrication, and use of tangible, often anatomically accurate or functionally representative, physical models for hands-on training, demonstration, or practice of practical skills and procedures, particularly in medical or technical fields.
Patents
Showing 1-10 of 14
Automated Drug Dispensing